Atypical Pediatric Demyelinating Diseases of the Central Nervous System

Troxell, Regina M.; Christy, Alison

doi:10.1007/s11910-019-1015-y

Cited by 12 publications

(8 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The age cutoff used for pediatric MS is the age of 16; however, the age 18 is also used by some researchers ( 39 ). The diagnosis of MS in youngsters is challenging since various conditions may present with similar clinical and radiological findings ( 40 ). The juvenile/adolescent cases identified in the current study are less than expected.…”

Section: Discussionmentioning

confidence: 99%

The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database

et al. 2020

View full text Add to dashboard Cite

Objective: To estimate current prevalence of multiple sclerosis (MS) in Greece using administrative data from the nationwide medicine prescription database. Methods: Prescription records of a 24-month period (June 2017–May 2019) were analyzed in order to identify cases of MS. Sex, age, and place of residence were recorded for each identified case. Prevalence of MS was calculated based on the updated records of the Greek population according to Hellenic Statistical Authority. Results: The 2-year cumulative period prevalence of MS was estimated to 197.8 per 100,000 (95% CI 197.6–198.0). In total, 21,218 patients (65.8% female) were identified. During this period, the prevalence of MS was 138.7 per 100,000 (95% CI 138.4–139.0) in men and 253.6 per 100,000 (95% CI 253.3–254.1) in women. Prevalence was higher in the 45–49 age group in both sexes. Analysis of the place of residence revealed higher prevalence in the Attica region and Western Greece while lower prevalence was observed in Northern Greece. No north–south latitude gradient was detected. Point prevalence on 1 January 2019 was calculated to 188.9 per 100,000 (95% CI 188.7–189.1). Regarding treatment, 73.1% of the identified cases received at least once a Disease Modifying Drug. Conclusions: According to this national-level study conducted in Greece, estimated prevalence of MS was found to be similar to those of other European countries. Heterogeneity of MS prevalence across the country was observed and needs further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database

et al. 2020

View full text Add to dashboard Cite

show abstract

“…4 Furthermore, demyelinating manifestations in SLE can also mimic multiple sclerosis, even fulfilling the McDonald criteria. 1…”

Section: Discussionmentioning

confidence: 99%

“…The myelin oligodendrocyte glycoprotein (MOG) is a myelin protein expressed in oligodendrocyte membranes and at the outermost surface of myelin sheaths. 1 Antibodies targeting MOG have been described to play a role in demyelinating diseases such as Multiple Sclerosis and Neuromyelitis Optica; 2 however, MOG-IgG-associated disorder (MOGAD) 3 is a unique entity among the demyelinating diseases. The disease’s phenotypes include acute disseminated encephalomyelitis (ADEM), transverse myelitis (TM) and Optic neuritis (ON).…”

Section: Introductionmentioning

confidence: 99%

MOG-IgG-associated disorder and systemic lupus erythematosus disease: Systematic review

Breis

Schlindwein

Bandeira

et al. 2020

Lupus

View full text Add to dashboard Cite

Introduction Myelin oligodendrocyte glycoprotein (MOG) is a nervous system protein expressed by oligodendrocytes to constitute the myelin sheath. Autoantibodies against MOG have been widely described in neurological and autoimmune diseases such as MOG-IgG-associated disorder (MOGAD). Although underlying mechanisms have not yet been understood, an overlap of MOGAD and Systemic Lupus Erythematosus (SLE) has been shown in the literature. Objectives The aim of this systematic review was to assess the possible correlations between MOGAD and SLE based on reported features found in the literature that support the association of the two. Methods A keyword-based literature search was conducted, applying a ten-year filter and using the following key-words: “MOG autoantibody-associated disease and Systemic Lupus Erythematosus”; “MOG and Systemic Lupus Erythematosus” “Anti-MOG and Lupus”; “MOG and SLE”; “MOG and LUPUS” on MEDLINE/PUBMED, ScienceDirect, SciELO, LILACS and Cochrane; and “MOG antibody-associated disease and SLE” on Google Scholar. Results Eleven publications reporting on the MOGAD and SLE correlation were included in qualitative synthesis: animal experiment (1), cross-sectional (3), prospective (2), retrospective (1), non-systematic review (3), and case report (1) studies. Conclusion Not much is known about the connection between MOG-IgG-associated disorder and SLE. Unfortunately, only observational studies have been conducted in humans so far, providing us with limited data. While MOGAD features have been reported to develop in SLE patients, this is not an universal finding. In fact, many different issues impair these results, making it difficult to match the findings of different studies.

show abstract

“…CLIPPERS is specified by determining punctate or curvilinear gadolinium-enhancing MRI lesions that are most noted in the pons [ 155 , 156 ].…”

Section: Multiple Sclerosis (Ms)mentioning

confidence: 99%

“…Intravenous and oral steroids can improve clinical and paraclinical effects rapidly. Long-term steroid-sparing agents such as azathioprine and mycophenolate have been used as well, except for immunomodulatory monoclonal antibodies like tocilizumab and rituximab [ 155 ].…”

Section: Multiple Sclerosis (Ms)mentioning

confidence: 99%

Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review

Gul¹,

Jafari

Shah

et al. 2020

IJMS

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS) which can lead to severe disability. Several diseases can mimic the clinical manifestations of MS. This can often lead to a prolonged period that involves numerous tests and investigations before a definitive diagnosis is reached. As well as the possibility of misdiagnosis. Molecular biomarkers can play a unique role in this regard. Molecular biomarkers offer a unique view into the CNS disorders. They help us understand the pathophysiology of disease as well as guiding our diagnostic, therapeutic, and prognostic approaches in CNS disorders. This review highlights the most prominent molecular biomarkers found in the literature with respect to MS and its related disorders. Based on numerous recent clinical and experimental studies, we demonstrate that several molecular biomarkers could very well aid us in differentiating MS from its related disorders. The implications of this work will hopefully serve clinicians and researchers alike, who regularly deal with MS and its related disorders.

show abstract

Atypical Pediatric Demyelinating Diseases of the Central Nervous System

Cited by 12 publications

References 75 publications

The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database

The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database

MOG-IgG-associated disorder and systemic lupus erythematosus disease: Systematic review

Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review

Contact Info

Product

Resources

About